

Washington University School of Medicine Digital Commons@Becker

Open Access Publications

6-1-2018

Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins

Elaine L Shelton

Vanderbilt University

Gautam K Singh

Washington University School of Medicine in St. Louis

Colin G Nichols

Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs


Recommended Citation

Shelton, Elaine L; Singh, Gautam K; and Nichols, Colin G, "Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins." *Seminars in Perinatology*, . . (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8217

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Available online at www.sciencedirect.com

Seminars in Perinatology

www.seminperinat.com

Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins

Elaine L. Shelton, PhD^{a,b,*}, Gautam K. Singh, MD^c, and
Colin G. Nichols, PhD^d

^aDepartment of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt and Vanderbilt University Medical Center, 2215 B Garland Ave., 1125 Light Hall/MRB4, Nashville, Tennessee 37232

^bDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee

^cDepartment of Pediatrics, Washington University School of Medicine, Saint Louis Children's Hospital, Saint Louis, Missouri

^dDepartment of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, Missouri

ARTICLE INFO

Keywords:

ductus arteriosus
PDA
KATP channel
novel drug targets

ABSTRACT

Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet, prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by imperfect therapies and wide variations in treatment strategy. There are few pharmacology-based tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for maintaining DA patency (PGE₁) as is needed to facilitate corrective surgery for ductus-dependent congenital heart defects. Unfortunately, all of these treatments are inefficient and are associated with concerning adverse effects. This review highlights novel potential DA drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The ductus arteriosus (DA) is a muscular artery that connects the fetal aorta and pulmonary artery, providing an integral shunt of the fetal circulation, essential for maintaining fetal wellbeing. *In utero*, the DA diverts approximately 90% of the right ventricular output away from the high-resistance pulmonary circulation and into the systemic umbilical-placental circulation where gas exchange can occur with maternal blood.¹ Postnatally, the DA normally closes within 72 hours after birth to facilitate perfusion of the newly-inflated lungs. Failure to close results in a persistent left-to-right shunt

termed patent ductus arteriosus (PDA). PDA affects up to 80% of premature infants² and accounts for 5–10% of all congenital heart defects in term infants.³ Hemodynamically significant PDA is associated with significant morbidities including neurodevelopmental impairment, intraventricular hemorrhage, pulmonary hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis (NEC), spontaneous intestinal perforation, and congestive heart failure.⁴ On the other hand, in ductus-dependent heart lesions, which account for 20–25% of all congenital heart defects, it is necessary that patency of the neonatal DA be maintained in order to preserve

This work was supported by R21HL132805 and AHA15SDG25280015 awarded to ELS and R35HL140024 awarded to CGN.

*Corresponding author at: Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt and Vanderbilt University Medical Center, 2215 B Garland Ave., 1125 Light Hall/MRB4, Nashville, Tennessee 37232.

E-mail address: Elaine.L.Shelton@vanderbilt.edu (E.L. Shelton).

<https://doi.org/10.1053/j.semp.2018.05.004>

0146-0005/© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

life-saving pulmonary or systemic circulation prior to corrective surgery.⁵

The fetal DA has intrinsic tone and requires dilating factors to maintain its patency *in utero*. Nitric oxide (NO) and prostaglandin E₂ (PGE₂) induce vessel relaxation by activating cGMP/PKG and cAMP/PKA signaling, respectively. While NO and PGE₂ are typically considered primary mediators of DA dilation, other factors, including potassium (K⁺) channels, adenosine, and atrial natriuretic peptide, also play a role.^{6–9} At birth, the DA constricts in response to the acute increase in oxygen (O₂) tension coupled with a loss of vasodilators. O₂ may act through several different pathways to exert its contractile effects on the DA,⁴ including cytochrome P450-mediated induction of endothelin 1¹⁰ and reactive oxygen species-inhibition of voltage-gated potassium (K⁺) channels (Kv1.5 and Kv2.1).¹¹ O₂ may also inhibit ATP-sensitive K⁺ (K_{ATP}) channels, resulting in membrane depolarization, activation of voltage dependent Ca²⁺ channels and increased intracellular Ca²⁺ accumulation.¹²

Current therapies

There are few pharmacology-based tools currently available for modulating DA tone.^{13–15} Introduced as a PDA therapy in the mid-1970s,^{16–18} the nonsteroidal anti-inflammatory drug (NSAID), indomethacin, facilitates DA closure by inhibiting cyclooxygenase COX-1 (PTGS1) and COX-2 (PTGS2) enzymes that are required for PGE₂ synthesis. A potent vasoconstrictor, indomethacin became the PDA drug of choice for many years, despite its association with renal dysfunction, platelet abnormalities, spontaneous intestinal perforation, and NEC.^{19–21} In the mid-1990s, ibuprofen emerged as an alternative to indomethacin, demonstrating equal efficacy, but with a decreased risk of NEC.^{22–24} However, use of either of these non-selective NSAIDs is still not ideal given their propensity to induce generalized vasoconstriction.^{20,21,25} In addition, indomethacin and ibuprofen are ineffective in approximately 30% of patients,²⁶ exposing such infants to increased risk of renal dysfunction, spontaneous intestinal perforation, and NEC with no therapeutic benefit. Recently, acetaminophen has been touted as the optimal choice for PDA management, because it is less likely to cause peripheral vasoconstriction and can be administered to infants with contraindications to NSAIDs.²⁷ Like the others, acetaminophen is a COX inhibitor, although it may not be as effective at blocking PGE₂ synthesis in immature vessels, potentially limiting its effectiveness in premature infants.²⁸

The ability of PGE₁ and PGE₂ to relax the *ex vivo* fetal lamb DA, first demonstrated in 1973 by Coceani and Olley,²⁹ led to initiation of several clinical trials to evaluate the efficacy of PGE₁ in maintenance of DA patency in infants with ductus-dependent congenital heart defects.^{30–32} Today, PGE₁ is still the only pharmacology-based therapy used to keep the DA open, despite its association with peripheral vasodilation, apnea, fever, and other physiologic disruptions.¹³ Prolonged treatment produces even more severe side effects, including cortical hyperostosis, gastric-outlet obstruction, and pseudo-Bartter syndrome.³³ In addition, while PDA therapies can be administered orally or intravenously, PGE₁-mediated DA

dilation requires continuous intravenous infusion, another significant limitation. Despite the inefficient nature of these current tools, relatively little effort has been expended over the last four decades to identify novel targets for pharmacology-based DA manipulation.

Towards specific DA-targeted therapies

Lack of progress towards novel DA drug development is not entirely unexpected given the low probability of success for drug development programs in general. A recent study,³⁴ the largest of its kind, reports that from 2005–2015 only 8.5 % of all industry-sponsored drug development programs ended in FDA approval. Moreover, the rate at which new drugs are validated and brought to market is staggeringly slow, with the average drug spending 8.14 years in clinical trials.³⁴ However, drugs with the highest likelihood of success target proteins with these key characteristics: druggability, enrichment in the tissue of interest, and demonstrated relevance to disease^{35,36} (Fig. 1). Targets with some precedent for binding a drug-like molecule are considered part of the “druggable genome”.³⁷ Most modern drugs act on receptors, enzymes, and ion channels/transporters. However, as the pharmaceutical industry devises new ways to target moieties such as protein–protein interactions and nucleic acids, the druggable genome will expand to include non-traditional targets. Accordingly, there will be room for expansion of the potential targets for DA therapy, beyond the PGE-pathway.

Traditional and non-traditional potential DA drug target candidates listed in Table 1, include novel targets identified as enriched in the DA, using array and RNA-seq analyses to identify the DA’s unique transcriptional identity (reviewed by Yarbboro et al., this issue).^{38–48} In the majority of these studies, the DA was compared to the ascending aorta, a natural choice given their close proximity and the shared neural crest origin of each vessel’s smooth muscle cells.⁴⁹ While these analyses are helpful, looking at DA-specific targets should be expanded to include a comparison to renal, mesenteric, and cerebral vessels, given the potential that novel drugs could, as do all current DA drugs, have adverse effects on these vascular




Fig. 1 – Characteristics of ideal drug targets. DA drug targets with the highest likelihood of receiving FDA approval are those that are druggable, enriched in the DA, and have an established link to PDA (denoted by asterisk in the central, overlapping region of the diagram).

Table 1 – Candidate DA drug targets. Representative list of potential DA drug targets. Candidates are classified as traditional (receptor, enzyme, ion channel or transporter) or non-traditional drug targets and are organized by protein category and type of evidence linking them to PDA (mouse model, human syndrome, or non-syndromic SNP).

	Receptors	Enzyme	Channel/transporter	Non-traditional targets
Enriched in the DA	Prostaglandin: PTGER4 Endothelin: EDNRA EDNRB Angiotensin: AGTR1 AGTR2 Glutamate: GRIK2 GRM3 Fibroblast Growth Factor: FGFR2 Roundabout Guidance: ROBO2	Prostaglandin Related: PTGIS PDE1B PDE1C PDE3B PDE4B PDE5A CYP1B1 Rho-associated: ROCK1 Smooth Muscle Related: MYLK ECM Related: CAMK1D ADAMTS9	ATP-gated K ⁺ Channel: ABCC9 KCNJ8 Voltage-gated K ⁺ Channel: Kv1.2 Kv1.5 Kv2.1 Ca ²⁺ -activated K ⁺ Channel: KCNMA1 KCNMB1 Chloride Channel: CLCA1 CLCA2 GABRA1 TRP Ca ²⁺ Channel: TRPM3	Transcription Factors: TFAP2B HOXB5 FOXF1A SOX9 HIF2a RUNX1 SCX DLX1 DLX2 Smooth Muscle Related: ACTA2 ACTG2 CNN1 DES MYH11 TAGLN Bone Morphogenic Protein: BMP2 BMP4 GREM1 ECM Related: FN1 TNN COL8A2 COL9A1 Cell Adhesion Related: CDH3 ICAM3 ICAM4 ICAM5 THBS1 Ligands: END1 SLIT2
Mouse models	Ptger4 ^{-/-} Notch2 ^{-/-} Notch2/Notch3 double ^{-/-}	Ptgs2 ^{-/-} Ptgs1/Ptgs2 double ^{-/-} Hpdg ^{-/-} Lox ^{-/-}	Sloco2a1 ^{-/-}	Tfap2b ^{-/-} Myocd ^{-/-} Myh11 ^{-/-} Jag1 ^{-/-} Brg1 ^{-/-} Bmp9 ^{-/-} with loss of Bmp10 Nfe2 ^{-/-} Itga2b ^{-/-}
Human Syndromes	TGFBRI/2 (Loeys-Dietz)	PTPN11 (Noonan) CHD7 (CHARGE) PTEN (VACTERL) EP300 (Rubinstein-Taybi) RAB23 (Carpenter)	ABCC9 (Cantu) KCNJ8 (Cantu) CACNA1C (Timothy)	TFAP2B (Char) SMADIP1 (Mowat-Wilson) TBX5 (Holt-Oram) CREBBP (Rubinstein-Taybi) TBX1 (DiGeorge) FLNA (Periventricular heterotopia) ZIC3 (Visceral heterotaxy) SEMA3E (CHARGE) FLBN (Larsen)
SNPs	Increased Risk of PDA: AGTR1 (rs5186) TGFBRI2 (rs934328) Increased Odds of Response to Indomethacin: CYP2C9 (rs2153628)	Decreased Risk of PDA: PTGIS (rs493694, rs693649)	N/A	Increased Risk of PDA: TFAP2B (rs987237) TRAF1 (rs1056567, rs3761846) PRDM6 (rs879255278) CREBBP (rs130021) Decreased Risk of PDA: ESR1 (rs2234693) IFN- γ (rs2430561)

beds.⁵⁰ While it is unlikely that any candidate will be exclusively expressed in the DA, those that are significantly enriched lend themselves to the possibility of targeting them with a relatively low “Goldilocks” dose of drug—one that would have just the right effect on the DA, but would be insufficient to act on other tissues given low expression of the target in those tissues.²⁶

Additionally, several transcriptome studies analyzed changes in gene expression in preterm vs term-gestation vessels. This is important to consider given that PDA most often occurs in the setting of prematurity and that immature DAs are less responsive to indomethacin and often lack the smooth muscle machinery to maintain DA closure even if initial constriction is achieved.⁵¹ Therefore, targeting pathways involved in fetal DA maturation may be key to developing therapies with a higher success rate in preterm infants. For instance, fetal DAs are significantly less responsive to oxygen-induced constriction than term-gestation vessels.^{52–54} Therefore, novel PDA therapies that can compensate for a diminished response to O₂ by promoting endothelin signaling or blocking K⁺ channels might be more effective at closing premature vessels.

Insights from animal studies

Animal models of PDA have been informative regarding disease pathways that could be therapeutically targeted.^{4,55} Interestingly, PDA is the most common cardiac anomaly in dogs. Studies show a sex-linked genetic predisposition, with certain breeds and female dogs being at higher risk.^{55–57} A similar sex-linked predisposition has been reported in humans⁵⁸ although this is not supported by more recent analyses.⁵⁹ Similarly, Brown Norway rats have a high prevalence of PDA, making them a popular experimental tool for identifying gene alterations in the setting of disease.⁴⁵ Finally, mouse models of PDA highlight the role of specific genes in DA development and function. Some of the latter have impaired smooth muscle development (*Tfap2b*^{−/−}, *Myocd*^{−/−}, *Myh1*^{−/−}), while others have impaired prostaglandin signaling (*Ptgs1/2*^{−/−}, *Ptger4*^{−/−}, *Sloca1*^{−/−}, *Hpdg*^{−/−}), which may seem counterintuitive given the primary role of PGE₂ in DA dilation. However, these animals suggest an additional role for prostaglandin signaling in maturing the contractile program of the ductus.⁶⁰ Still other animal models lack various genes that are key in development pathways, including Notch (*Notch2/3*^{−/−}, *Jag1*^{−/−}), BMP (*BMP9/10*^{−/−}), chromatin remodeling (*Brg1*^{−/−}), platelet homeostasis (*Nfe2*^{−/−}, *Itga2b*^{−/−}), or elastin and collagen crosslinking (*Lox*^{−/−}).⁶¹ These animals not only give molecular insight into disease-causing mechanisms, they also provide established *in vivo* platforms for pre-clinical validation of second-generation PDA drugs.

Insights from human studies

Results of animal studies are not always faithful predictors of patient outcomes,⁶² highlighting the need for human genetic studies.⁶³ A representative set of the more than 100 single-gene mutation syndromes featuring PDA that have now been

identified^{55,64,65} is listed in Table 1. Many of these syndromes also feature complicated congenital heart defects, making it difficult to parse out whether PDA is a primary lesion or the result of other structural and hemodynamic anomalies. Therefore, identifying gene variants associated with non-syndromic PDA may be more informative for sporadically occurring PDA, which makes up the vast majority (90%) of all PDA cases.⁶⁶ Single nucleotide polymorphisms (SNPs) associated with PDA²⁶ or response to indomethacin⁶⁷ have also been reported (Table 1), although it has been difficult to confirm these findings in replication cohorts.^{68,69}

Proof of concept

Interestingly, targets of current PDA therapeutics fulfill all three of the key characteristics of successful drug targets illustrated in Figure 1. Indomethacin, ibuprofen, and acetaminophen all inhibit COX enzymes encoded by *PTGS1* and *PTGS2* genes. These enzymes catalyze PGE₂ synthesis, which subsequently regulates DA tone by binding to the DA-enriched receptor, *PTGER4*. Mice lacking these enzymes or the receptor have a lethal PDA phenotype,^{44,70–73} demonstrating relevance of these targets to this disease. Therefore, it may be reasonable to assume that novel DA drug targets with the best chance of having clinical success will conform to a similar pattern. As one example, K_{ATP} channels possess all three key characteristics listed above. These channels are hetero-octameric complexes of pore-forming inward rectifier K⁺ channel subunits (Kir6.1 or Kir6.2) and regulatory sulfonylurea receptor subunits (SUR1, SUR2A, or SUR2B). Channel isoforms have distinct pharmacological and physiological characteristics and are expressed in a tissue-specific manner (Table 2), making them potentially ideal targets for DA-selective therapies.⁷⁴

A regulatory link between K_{ATP} channels and DA tone is becoming increasingly apparent. Vascular K_{ATP} channels, formed of the Kir6.1/SUR2B isoform combination, are developmentally regulated and significantly enriched in the DA compared to other vessels.^{38–42,45,48} Animal studies have shown that the DA constricts in response to glibenclamide,^{12,75} a non-specific K_{ATP} channel inhibitor commonly used to treat diabetes. Conversely, fetal or neonatal exposure to diazoxide, a K_{ATP} channel activator, inhibited DA constriction in rats,⁷⁶ and was reported to cause DA reopening in hypoglycemic infants.⁷⁷ Most notably, 50% of patients with Cantu syndrome, caused by activating mutations in Kir6.1 or SUR2B, have a clinically significant PDA that is often resistant

Table 2 – Isoform-specific expression of K_{ATP} channel subunits.

Subunits	Tissue
Kir6.1/SUR2B	Vascular smooth muscle and endothelium
KIR6.1/SUR2B	Visceral smooth muscle
Kir6.2/SUR2A	Skeletal muscle
Kir6.1/SUR2	Cardiac conduction system
Kir6.2/SUR1,2	Cardiomyocytes
Kir6.2/SUR1	Pancreatic β cells, brain




Fig. 2 – Isolated mouse DAs were mounted in microvessel perfusion chambers for use in pressure myography assays. Vessels were treated with increasing concentrations of pinacidil or VU063. Changes in lumen diameter were measured and plotted as a percent change from the initial lumen diameter reading under baseline (bl) conditions. Pinacidil dilated the DA, while VU063 had no effect.

to indomethacin therapy, thus requiring surgical ligation to achieve closure.⁷⁸

Capitalizing on the druggability and therapeutic potential of K_{ATP} channels, several groups, including our own, are working to develop subunit-specific activators and inhibitors.^{79,80} Using a thallium flux-based high-throughput screen, we identified a very potent novel K_{ATP} channel agonist (VU063), with preferential activity towards the pancreatic/neuronal channel isoform (Kir6.2/SUR1).^{74,79} We performed pressure myography assays on mouse DAs as previously described^{41,81} to test the specificity and vasoactive potential of this compound (Fig. 2). As expected, the SUR2-preferring K_{ATP} channel activator, pinacidil, dilated the DA in a dose-dependent manner, but VU063 had no effect on DA tone. Thus, while VU063 would, just like diazoxide, be conducive for treating hyperinsulinemia, unlike diazoxide it would not induce off-target vascular effects. Along these lines, it is likely that future studies will identify small molecule antagonists/agonists that preferentially target the vascular channel isoform (Kir6.1/SUR2B), which will allow for a more specific way to modulate DA tone.

Perspective and prospects

In the 45 years since the first reports of indomethacin-induced DA closure,^{16–18,29,82,83} relatively little headway has been made in developing novel approaches for therapeutic modulation of DA tone. As a consequence, there has been little progress in establishing a standard of care over the subsequent decades, leading to significant variability in treatment strategies amongst neonatal care centers and even between providers in a single care center.^{84,85} As we learn more about the DA, it is becoming clear that PDA is a deceptively complex condition that will likely benefit more from personalized medicine rather than a *one-pathway-fits all* approach to therapeutics. In lieu of redundant retrospective case analyses, a greater emphasis should be placed on multidisciplinary efforts to identify DA-modulating pathways outside of the prostaglandin signaling cascade and to develop specific pharmacological modifiers of those targets.

Moving towards this goal, increased access to human tissue repositories⁸⁶ coupled with the ability to perform large-scale GWAS and other genome-wide studies will uncover new PDA-associated genes. Furthermore, these studies will provide important pharmacogenetic information that could be used at the bedside to prospectively determine the likelihood of an individual patient responding to indomethacin, thereby shielding non-responders from unnecessary exposure.⁸⁷ Moreover, emerging technologies including the generation of tissue-engineered ductus vessels⁸⁸ and the creation of immortalized human DA cell lines for use in high-throughput small molecule screens will provide novel tools to identify and validate second generation DA drugs, setting the stage for rapid advances towards novel DA therapeutic development.

Disclosures

We have no conflicts of interest to report.

REFERENCES

- Rudolph AM. Fetal and neonatal pulmonary circulation. *Annu Rev Physiol.* 1979;41:383–395.
- Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. *Pediatrics.* 2006;117(4):1113–1121.
- Dice JE, Bhatia J. Patent ductus arteriosus: an overview. *J Pediatr Pharmacol Ther.* 2007;12(3):138–146.
- Stoller JZ, Demmauro SB, Dagle JM, Reese J. Current perspectives on pathobiology of the ductus arteriosus. *J Clin Exp Cardiol.* 2012;8(1).
- Schneider M, Zartner P, Sidiropoulos A, Konertz W, Hausdorf G. Stent implantation of the arterial duct in newborns with duct-dependent circulation. *Eur Heart J.* 1998;19(9):1401–1409.
- Akaike T, Minamisawa S. Role of ion channels in ductus arteriosus closure. *Hum Genet Embryol.* 2014(3):3.
- Mentzer RM Jr., Ely SW, Lasley RD, Mainwaring RD, Wright EM Jr., Berne RM. Hormonal role of adenosine in maintaining patency of the ductus arteriosus in fetal lambs. *Ann Surg.* 1985;202(2):223–230.
- Toyoshima K, Momma K, Imamura S, Nakanishi T. In vivo dilatation of the postnatal ductus arteriosus by atrial natriuretic peptide in the rat. *Neonatology.* 2007;92(2):139–144.
- Andersson S, Tikkanen I, Pesonen E, Meretoja O, Hynynen M, Fyhrquist F. Atrial natriuretic peptide in patent ductus arteriosus. *Pediatr Res.* 1987;21(4):396–398.
- Cocceani F, Kelsey L, Seidlitz E, Korzekwa K. Inhibition of the contraction of the ductus arteriosus to oxygen by 1-amino-benzotriazole, a mechanism-based inactivator of cytochrome P450. *Br J Pharmacol.* 1996;117(7):1586–1592.
- Michelakis ED, Rebeyka I, Wu X, et al. O_2 sensing in the human ductus arteriosus: regulation of voltage-gated K^+ channels in smooth muscle cells by a mitochondrial redox sensor. *Circ Res.* 2002;91(6):478–486.
- Waleh N, Reese J, Kajino H, et al. Oxygen-induced tension in the sheep ductus arteriosus: effects of gestation on potassium and calcium channel regulation. *Pediatr Res.* 2009;65(3):285–290.
- Lewis AB, Freed MD, Heymann MA, Roehl SL, Kensey RC. Side effects of therapy with prostaglandin E1 in infants with

- critical congenital heart disease. *Circulation*. 1981;64(5):893–898.
14. Coceani F. Therapeutic manipulation of the ductus arteriosus: current options and future prospects. *Pol Arch Med Wewn*. 2014;124(1-2):58–64.
 15. Olley PM, Coceani F. Prostaglandins and the ductus arteriosus. *Annu Rev Med*. 1981;32:375–385.
 16. Coceani F, Olley PM, Bodach E. Lamb ductus arteriosus: effect of prostaglandin synthesis inhibitors on the muscle tone and the response to prostaglandin E₂. *Prostaglandins*. 1975;9(2):299–308.
 17. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. *N Engl J Med*. 1976;295(10):526–529.
 18. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. *N Engl J Med*. 1976;295(10):530–533.
 19. Mehta S, Younoszai A, Pietz J, Achanti B. Pharmacological closure of the patent ductus arteriosus. *Images Paediatr Cardiol*. 2003;5(1):1–15.
 20. Christmann V, Liem KD, Semmekrot BA, van de Bor M. Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. *Acta Paediatr*. 2002;91(4):440–446.
 21. Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. *N Engl J Med*. 1993;329(22):1602–1607.
 22. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. *Eur J Pediatr*. 2005;164(3):135–140.
 23. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ. Treatment of patent ductus arteriosus with ibuprofen. *Arch Dis Child Fetal Neonatal Ed*. 1997;76(3):F179–184.
 24. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. *N Engl J Med*. 2000;343(10):674–681.
 25. Reese J, Shelton EL, Slaughter JC, McNamara PJ. Prophylactic indomethacin revisited. *J Pediatr*. 2017;186:11–14 e11.
 26. Lewis TR, Shelton EL, Van Driest SL, Kannankeril PJ, Reese J. Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment. *Semin Fetal Neonatal Med*. 2018 [Epub ahead of print].
 27. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. *Pediatrics*. 2011;128(6):e1618–1621.
 28. El-Khuffash A, Jain A, Corcoran D, et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. *Pediatr Res*. 2014;76(3):238–244.
 29. Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. *Can J Physiol Pharmacol*. 1973;51(3):220–225.
 30. Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. *Lancet*. 1975;1(7899):140–142.
 31. Freed MD, Heymann MA, Lewis AB, Roehl SL, Kensey RC. Prostaglandin E₁ infants with ductus arteriosus-dependent congenital heart disease. *Circulation*. 1981;64(5):899–905.
 32. Olley PM, Coceani F, Bodach E. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. *Circulation*. 1976;53(4):728–731.
 33. Talosi G, Katona M, Turi S. Side-effects of long-term prostaglandin E₁ treatment in neonates. *Pediatr Int*. 2007;49(3):335–340.
 34. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics* 2018. [Epub ahead of print].
 35. Finan C, Gaulton A, Kruger FA, et al. The druggable genome and support for target identification and validation in drug development. *Sci Transl Med*. 2017(383):9.
 36. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? *Drug Discov Today*. 2011;16(23-24):1037–1043.
 37. Hopkins AL, Groom CR. The druggable genome. *Nat Rev Drug Discov*. 2002;1(9):727–730.
 38. Bokenkamp R, van Brempt R, van Munsteren JC, et al. Dlx1 and Rgs5 in the ductus arteriosus: vessel-specific genes identified by transcriptional profiling of laser-capture microdissected endothelial and smooth muscle cells. *PLoS One*. 2014;9(1):e86892.
 39. Costa M, Barogi S, Socci ND, et al. Gene expression in ductus arteriosus and aorta: comparison of birth and oxygen effects. *Physiol Genomics*. 2006;25(2):250–262.
 40. Jin MH, Yokoyama U, Sato Y, et al. DNA microarray profiling identified a new role of growth hormone in vascular remodeling of rat ductus arteriosus. *J Physiol Sci*. 2011;61(3):167–179.
 41. Shelton EL, Ector G, Galindo CL, et al. Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone. *Physiol Genomics*. 2014;46(13):457–466.
 42. Yokoyama U, Sato Y, Akaike T, et al. Maternal vitamin A alters gene profiles and structural maturation of the rat ductus arteriosus. *Physiol Genomics*. 2007;31(1):139–157.
 43. Goyal R, Goyal D, Longo LD, Clyman RI. Microarray gene expression analysis in ovine ductus arteriosus during fetal development and birth transition. *Pediatr Res*. 2016;80(4):610–618.
 44. Gruzdev A, Nguyen M, Kovarova M, Koller BH. PGE₂ through the EP₄ receptor controls smooth muscle gene expression patterns in the ductus arteriosus critical for remodeling at birth. *Prostaglandins Other Lipid Mediat*. 2012;97(3-4):109–119.
 45. Hsieh YT, Liu NM, Ohmori E, et al. Transcription profiles of the ductus arteriosus in Brown-Norway rats with irregular elastic fiber formation. *Circ J*. 2014;78(5):1224–1233.
 46. Mueller PP, Drynda A, Goltz D, Hoehn R, Hauser H, Peuster M. Common signatures for gene expression in postnatal patients with patent arterial ducts and stented arteries. *Cardiol Young*. 2009;19(4):352–359.
 47. Parikh P, Bai H, Swartz MF, Alfieri GM, Dean DA. Identification of differentially regulated genes in human patent ductus arteriosus. *Exp Biol Med*. 2016;241(18):2112–2118.
 48. Waleh N, Barrette AM, Dagle JM, et al. Effects of advancing gestation and non-caucasian race on ductus arteriosus gene expression. *J Pediatr*. 2015;167(5):1033–1041.
 49. Pfaltzgraff ER, Shelton EL, Galindo CL, et al. Embryonic domains of the aorta derived from diverse origins exhibit distinct properties that converge into a common phenotype in the adult. *J Mol Cell Cardiol*. 2014;69:88–96.
 50. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? *Semin Perinatol*. 2012;36(2):123–129.
 51. Quinn D, Cooper B, Clyman RI. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. *Pediatrics*. 2002;110(1 Pt 1):e10.
 52. Dunn PM, Speidel BD. Use of oxygen to close patent ductus arteriosus in preterm infants. *Lancet*. 1973;2(7824):333–334.
 53. Noel S, Cassin S. Maturation of contractile response of ductus arteriosus to oxygen and drugs. *Am J Physiol*. 1976;231(1):240–243.
 54. Reese J, O'Mara PW, Poole SD, et al. Regulation of the fetal mouse ductus arteriosus is dependent on interaction of nitric oxide and COX enzymes in the ductal wall. *Prostaglandins Other Lipid Mediat*. 2009;88(3-4):89–96.
 55. Bokenkamp R, DeRuiter MC, van Munsteren C, Gittenberger-de Groot AC. Insights into the pathogenesis and genetic background of patency of the ductus arteriosus. *Neonatology*. 2010;98(1):6–17.

56. Patterson DF, Pyle RL, Buchanan JW, Trautvetter E, Abt DA. Hereditary patent ductus arteriosus and its sequelae in the dog. *Circ Res*. 1971;29(1):1–13.
57. Broadbudd K, Tillson M. Patent ductus arteriosus in dogs. *Compend Contin Educ Vet*. 2010;32(9):E3.
58. Schneider DJ. The patent ductus arteriosus in term infants, children, and adults. *Semin Perinatol*. 2012;36(2):146–153.
59. Tripathi A, Black GB, Park YM, Jerrell JM. Prevalence and management of patent ductus arteriosus in a pediatric medicaid cohort. *Clin Cardiol*. 2013;36(9):502–506.
60. Reese J, Waleh N, Poole SD, Brown N, Roman C, Clyman RI. Chronic in utero cyclooxygenase inhibition alters PGE2-regulated ductus arteriosus contractile pathways and prevents postnatal closure. *Pediatr Res*. 2009;66(2):155–161.
61. Staiculescu MC, Kim J, Mecham RP, Wagenseil JE. Mechanical behavior and matrisome gene expression in the aneurysm-prone thoracic aorta of newborn lysyl oxidase knockout mice. *Am J Physiol Heart Circ Physiol*. 2017;313(2):H446–H456.
62. Bracken MB. Why animal studies are often poor predictors of human reactions to exposure. *J R Soc Med*. 2009;102(3):120–122.
63. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. *Nat Rev Drug Discov*. 2013;12(8):581–594.
64. Hajj H, Dagle JM. Genetics of patent ductus arteriosus susceptibility and treatment. *Semin Perinatol*. 2012;36(2):98–104.
65. Patel PM, Momany AM, Schaa KL, et al. Genetic modifiers of patent ductus arteriosus in term infants. *J Pediatr*. 2016;176:57–61 e51.
66. Mani A, Meraji SM, Houshyar R, et al. Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. *Proc Natl Acad Sci U S A*. 2002;99(23):15054–15059.
67. Smith CJ, Ryckman KK, Bahr TM, Dagle JM. Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus. *Pediatr Res*. 2017;82(5):776–780.
68. Kawase K, Sugiura T, Nagaya Y, et al. Single nucleotide polymorphisms in AGTR1, TFAP2B, and TRAF1 are not associated with the incidence of patent ductus arteriosus in Japanese preterm infants. *Pediatr Int*. 2016;58(6):461–466.
69. Dagle JM, Lepp NT, Cooper ME, et al. Determination of genetic predisposition to patent ductus arteriosus in preterm infants. *Pediatrics*. 2009;123(4):1116–1123.
70. Loftin CD, Trivedi DB, Tiano HF, et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. *Proc Natl Acad Sci U S A*. 2001;98(3):1059–1064.
71. Reese J, Anderson JD, Brown N, Roman C, Clyman RI. Inhibition of cyclooxygenase isoforms in late—but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice. *Am J Physiol Regul Integr Comp Physiol*. 2006;291(6):R1717–1723.
72. Reese J, Paria BC, Brown N, Zhao X, Morrow JD, Dey SK. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. *Proc Natl Acad Sci U S A*. 2000;97(17):9759–9764.
73. Segi E, Sugimoto Y, Yamasaki A, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. *Biochem Biophys Res Commun*. 1998;246(1):7–12.
74. Kharade SV, Nichols C, Denton JS. The shifting landscape of KATP channelopathies and the need for ‘sharper’ therapeutics. *Future Med Chem*. 2016;8(7):789–802.
75. Nakanishi T, Gu H, Hagiwara N, Momma K. Mechanisms of oxygen-induced contraction of ductus arteriosus isolated from the fetal rabbit. *Circ Res*. 1993;72(2):1218–1228.
76. Toyoshima K, Momma K, Ishii T, Nakanishi T. Dilatation of the ductus arteriosus by diazoxide in fetal and neonatal rats. *Pediatr Int*. 2017;59(12):1246–1251.
77. Demirel F, Unal S, Cetin II, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. *J Pediatr Endocrinol Metab*. 2011;24(7–8):603–605.
78. Grange DK, Nichols CG, Singh GK. Cantu Syndrome and related disorders. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA, 1993.
79. Raphemot R, Swale DR, Dadi PK, et al. Direct activation of beta-cell KATP channels with a novel xanthine derivative. *Mol Pharmacol*. 2014;85(6):858–865.
80. Dabrowski M, Ashcroft FM, Ashfield R, et al. The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. *Diabetes*. 2002;51(6):1896–1906.
81. Hooper CW, Delaney C, Streeter T, et al. Selective serotonin reuptake inhibitor exposure constricts the mouse ductus arteriosus in utero. *Am J Physiol Heart Circ Physiol*. 2016;311(3):H572–581.
82. Starling MB, Elliott RB. The effects of prostaglandins, prostaglandin inhibitors, and oxygen on the closure of the ductus arteriosus, pulmonary arteries and umbilical vessels in vitro. *Prostaglandins*. 1974;8(3):187–203.
83. Sharpe GL, Thalme B, Larsson KS. Studies on closure of the ductus arteriosus. XI. Ductal closure in utero by a prostaglandin synthetase inhibitor. *Prostaglandins*. 1974;8(5):363–368.
84. Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes. *J Perinatol*. 2007;27(3):164–170.
85. Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. *Arch Dis Child Fetal Neonatal Ed*. 2007;92(6):F498–502.
86. McGregor TL, Van Driest SL, Brothers KB, Bowton EA, Muglia LJ, Roden DM. Inclusion of pediatric samples in an opt-out biorepository linking DNA to de-identified medical records: pediatric BioVU. *Clin Pharmacol Ther*. 2013;93(2):204–211.
87. Carlson B. Vanderbilt pioneers bedside genetics. *Biotechnol Healthc*. 2012;9(2):31–32.
88. Saito J, Yokoyama U, Nicho N, et al. Tissue-type plasminogen activator contributes to remodeling of the rat ductus arteriosus. *PLoS One*. 2018;13(1):e0190871.